返回
Starpharma Holdings Ltd（SPHRY）價格
SPHRY 股價走勢圖
SPHRY 收益
Starpharma Holdings Ltd
$2.3
-11.53%
$-0.3
收盤價：Jan 16, 16:00:00 GMT-5
$2.3
0%
$0
盤後：Jan 16, 20:00:00 GMT-5
關鍵數據
前收市價
$2.6
開盤價
$2.3
當日範圍
$2.3 - $2.3
52週區間
$0.47 - $2.86
交易量
1.1K
平均成交量
1.0K
每股盈餘 (TTM)
-0.16
股息收益率
--
市值
$96.1M
什麼是 SPHRY？
Starpharma Holdings Ltd. engages in the research, development, and commercialization of dendrimer products for pharmaceutical and healthcare applications. The firm's principal activities are focused on the research, development and commercialization of dendrimer technology for pharmaceutical and healthcare applications. The firm's portfolio of dendrimer-based products includes three clinical-stage dendrimer enhanced product (DEP) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over the counter (OTC) products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, the Company has a preclinical pipeline of DEP radiopharmaceuticals in development. The company also manufactures and sells SPL7013 (astodrimer sodium) proprietary products: VivaGel BV, Viraleze nasal spray, and VivaGel condom. The firm has applied its DEP technology to the innovative area of antibody-drug conjugates.